Raphael Pharmaceutical Inc.
RAPH OTC
SEC CIK 1415397
Follow Raphael Pharmaceutical
Weekly email: filings, results, news
Net income
−$223K
+30.7% vs same quarter last year
EPS, diluted
$0.01
−50% vs same quarter last year
Operating cash flow
$0
+100% vs same quarter last year
Operating income
−$199K
+36.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$1.3M |
| FY24 | −$1.5M |
| FY23 | −$1.3M |
| FY22 | −$3.4M |
| FY21 | −$1.6M |
| FY20 | −$718K |
| FY19 | - |
News
No stories filed under Raphael Pharmaceutical yet - coverage appears here as the news feed clusters it.